소마젠

950200KOSDAQ그외 기타 전문, 과학 및 기술 서비스업

50.1 / 100

Reference Date: 2026-07-24

Financial Score12.5 / 40

News Sentiment20.6 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Rose 7.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

SomaGen provides diverse genomic analysis services, including NGS, CES, single-cell analysis, and proteomics, collaborating with institutions like the US NIH and global pharmaceutical companies through a B2B model, establishing a strong presence in the North American market. It also expands into the B2C sector with DTC genetic testing and microbiome analysis services, leveraging partnerships with companies such as 10x Genomics and Olink Proteomics to enhance its technological capabilities.

Number of Employees

88people

Average Salary

78.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 42.304.0Point

PBR

—Industry Average 1.083.5Point

ROE

-15.09Industry Average 0.940.0Point

Well below industry avg

Debt Ratio

33.35Industry Average 12.510.0Point

2.7x industry avg (risky)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲29.7% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -15.9% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 82.5

Positive
소마젠, 가장 까다로운’ 뉴욕 임상검사 관문 넘었다…유전체 진단시...
소마젠이 뉴욕 임상 검사실 인증을 획득하여 유전체 진단 시장 진출에 큰 도약을 이루었다.
Positive
소마젠, 자본잉여금 1135억 활용 결손금 보전... "재무구조 획기적...
소마젠은 자본잉여금을 활용해 누적 결손금을 보전함으로써 재무구조를 크게 개선했다.
Positive
소마젠, 자본잉여금 감액 통한 결손금 보전
소마젠의 자본잉여금 감액으로 인해 누적 결손금이 보전되어 재무 건전성이 개선될 것으로 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 2,720Won52-week high 4,12552-week low 2,410

1-month return5.0Point

1m +7.09% (rising)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral투자판단관련주요경영사항 (자본잉여금 감액 및 결손금 보전 결정(이사회 결의))2026-06-30